Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports

Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports

BackgroundPatients with human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) have poor prognosis. Trastuzumab deruxtecan (T-DXd) is the first targeted therapy approved for the treatment of patients with HER2-mutant metastatic NSCLC, but the evidence in those with...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan Meng, Yanping Du, Xiaolin Liu, Jue Huang, Hanhan Chen, Chunxia He
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Immunology
Subjects:
trastuzumab deruxtecan
non-small cell lung cancer
human epidermal growth factor receptor 2
mutation
case series
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1631768/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items